stockrowOrganon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
Follow OGN
Alert me
Organon & Co. (OGN) Debt to equity
Organon & Co.'s debt to equity at the end of the quarter to 30 September 2026 was 7.2×, down 4.3× from fiscal 2025 (11.5×). Over the past ten years it has ranged from −125× (fiscal 2023) to 18.8× (fiscal 2024); the current reading is higher than 88% of that period. That is above the Drug Manufacturers General industry median of 0.6× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 11.5× | (38.90%) |
| FY2024 | 18.8× | — |
| FY2023 | −125× | — |
| FY2022 | −10.0× | — |
| FY2021 | −6.1× | — |
| FY2020 | 0.0× | (66.07%) |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 7.2× | (15.66%) |
| Jun 2026 | 8.5× | (10.41%) |
| Mar 2026 | 9.5× | (17.44%) |
| Dec 2025 | 11.5× | 17.97% |
| 25 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| AMRN Amarin Corporation PLC compare | 0.0× |
| SNY Sanofi compare | 0.2× |
| BIIB Biogen Inc. compare | 0.4× |
| NVO Novo Nordisk A/S compare | 0.6× |
| PFE Pfizer Inc. compare | 0.7× |
| GRFS Grifols, S.A. compare | 1.1× |
| GSK GSK PLC Sponsored ADR compare | 1.3× |
| BMY Bristol Myers Squibb Company compare | 1.8× |
| OGN Organon & Co. | 7.2× |
| Drug Manufacturers General industry median | 0.6× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on OGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement